Fate Therapeutics Inc (FATE)

[jondoeuk]

(OT) Modulus Therapeutics, is engineering next-gen immune cell therapies, starting with NK cells rationally designed for the treatment of solid tumours. Modulus' Convergent Design platform combines genetic engineering, machine learning, and high-throughput screening to systematically converge on optimised cell designs. Modulus is committed to the discovery of cell therapies to treat a broad set of patient populations not currently served by existing treatments and will use its platform to enable partners and develop an internal pipeline of therapeutics.